Published in US Ophthalmic Rev on January 01, 2014
Association of bilirubin and malondialdehyde levels with retinopathy in type 2 diabetes mellitus. Indian J Endocrinol Metab (2015) 0.79
Overview of Ocular Anti-Vascular Endothelial Growth Factor Therapy in the Management of Diabetic Eye Complications. Diabetes Spectr (2016) 0.75
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ (1998) 32.73
Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med (2010) 10.75
Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology (2003) 8.98
Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med (2009) 6.75
Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology (2012) 6.35
Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res (2007) 3.67
Visual impairment in diabetes. Ophthalmology (1984) 3.64
A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Prog Neuropsychopharmacol Biol Psychiatry (2003) 3.42
Risks of intravitreous injection: a comprehensive review. Retina (2004) 3.39
Diabetic retinopathy. Diabetes Care (1998) 3.39
Inflammation in diabetic retinopathy. Prog Retin Eye Res (2011) 3.29
Diabetic retinopathy. Diabetes Care (2004) 2.97
The economic burden of major adult visual disorders in the United States. Arch Ophthalmol (2006) 2.92
Risk factors for diabetic retinopathy in self-reported rural population with diabetes. J Postgrad Med (2009) 2.67
Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nat Med (2009) 2.31
Improvement of visual acuity in eyes with diabetic macular edema after treatment with pars plana vitrectomy. Ophthalmologica (2004) 2.28
Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol (2008) 2.26
Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005-2050. Arch Ophthalmol (2008) 2.14
TNF-alpha mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations. Mol Vis (2009) 2.08
A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes. Diabetes (2004) 2.03
Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappaB. Diabetes (2004) 2.02
Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J Biochem (2012) 1.93
Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol (2011) 1.92
Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci (2004) 1.89
VEGF activation of protein kinase C stimulates occludin phosphorylation and contributes to endothelial permeability. Invest Ophthalmol Vis Sci (2006) 1.86
Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and the inner limiting membrane. Retina (2000) 1.84
Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr Diab Rep (2012) 1.83
Targeted deletion of Vegfa in adult mice induces vision loss. J Clin Invest (2012) 1.79
A multifocal electroretinogram model predicting the development of diabetic retinopathy. Prog Retin Eye Res (2006) 1.65
Salicylate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy. Diabetes (2007) 1.61
Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia (2009) 1.59
Diabetes reduces basal retinal insulin receptor signaling: reversal with systemic and local insulin. Diabetes (2006) 1.58
Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes (2007) 1.57
Intraocular pressure alterations following intravitreal triamcinolone acetonide. Br J Ophthalmol (2006) 1.55
Decreased optical coherence tomography-measured pericentral retinal thickness in patients with diabetes mellitus type 1 with minimal diabetic retinopathy. Br J Ophthalmol (2007) 1.48
TNFalpha is required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis. Invest Ophthalmol Vis Sci (2011) 1.47
Neurodegenerative influence of oxidative stress in the retina of a murine model of diabetes. Diabetologia (2010) 1.42
Role of frequency doubling technology perimetry in screening of diabetic retinopathy. Indian J Ophthalmol (2006) 1.39
Detection of early diabetic change with optical coherence tomography in type 2 diabetes mellitus patients without retinopathy. Ophthalmologica (2005) 1.34
Early neurodegeneration in the retina of type 2 diabetic patients. Invest Ophthalmol Vis Sci (2012) 1.32
Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes. Invest Ophthalmol Vis Sci (2008) 1.32
Fenofibrate - a potential systemic treatment for diabetic retinopathy? Am J Ophthalmol (2012) 1.31
Multifocal electroretinogram delays predict sites of subsequent diabetic retinopathy. Invest Ophthalmol Vis Sci (2004) 1.30
Local diabetic retinopathy prediction by multifocal ERG delays over 3 years. Invest Ophthalmol Vis Sci (2008) 1.29
Multifocal electroretinograms predict onset of diabetic retinopathy in adult patients with diabetes. Invest Ophthalmol Vis Sci (2011) 1.26
Diabetic retinopathy in type 1 diabetes-a contemporary analysis of 8,784 patients. Diabetologia (2011) 1.25
Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina (2007) 1.22
Visual side effects of successful scatter laser photocoagulation surgery for proliferative diabetic retinopathy: a literature review. Retina (2007) 1.21
Retinopathy is independently related to microalbuminuria in type 2 diabetes mellitus. Clin Nephrol (1999) 1.15
Vitrectomy results for diffuse diabetic macular edema with and without inner limiting membrane removal. Eur J Ophthalmol (2004) 1.13
Hyperglycemia, blood pressure, and the 9-year incidence of diabetic retinopathy: the Barbados Eye Studies. Ophthalmology (2005) 1.13
Differential association of serum lipids with diabetic retinopathy and diabetic macular edema. Invest Ophthalmol Vis Sci (2011) 1.10
Severity of diabetic retinopathy and health-related quality of life: the Los Angeles Latino Eye Study. Ophthalmology (2010) 1.07
Inner retinal visual dysfunction is a sensitive marker of non-proliferative diabetic retinopathy. Br J Ophthalmol (2011) 1.06
Comparison of the short-term effects of intravitreal triamcinolone acetonide and bevacizumab injection for diabetic macular edema. Korean J Ophthalmol (2011) 1.06
Serum lipids and diabetic retinopathy: A cross-sectional study. Indian J Endocrinol Metab (2012) 1.05
Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion. Retina (2011) 1.04
Factors associated with visual acuity outcomes after vitrectomy for diabetic macular edema: diabetic retinopathy clinical research network. Retina (2010) 1.04
Diabetic retinopathy and VEGF. Open Ophthalmol J (2013) 1.03
Does neuronal damage precede vascular damage in subjects with type 2 diabetes mellitus and having no clinical diabetic retinopathy? Ophthalmic Res (2011) 1.02
Visual dysfunction associated with diabetic retinopathy. Curr Diab Rep (2010) 1.01
Müller glial dysfunction during diabetic retinopathy in rats is linked to accumulation of advanced glycation end-products and advanced lipoxidation end-products. Diabetologia (2010) 1.01
Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmol (2007) 1.00
Novel atypical PKC inhibitors prevent vascular endothelial growth factor-induced blood-retinal barrier dysfunction. Biochem J (2012) 1.00
Automated grading for diabetic retinopathy: a large-scale audit using arbitration by clinical experts. Br J Ophthalmol (2010) 0.99
Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema. Clin Interv Aging (2013) 0.99
Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies. Eye (Lond) (2011) 0.96
Nerve fibre layer thinning in patients with preclinical retinopathy. Can J Ophthalmol (2009) 0.95
Protective role of pigment epithelium-derived factor (PEDF) in early phase of experimental diabetic retinopathy. Diabetes Metab Res Rev (2009) 0.95
Ruboxistaurin: PKC-beta inhibition for complications of diabetes. Expert Opin Pharmacother (2009) 0.95
Early neural and vascular changes in the adolescent type 1 and type 2 diabetic retina. Retina (2012) 0.94
Differential roles of hyperglycemia and hypoinsulinemia in diabetes induced retinal cell death: evidence for retinal insulin resistance. PLoS One (2011) 0.94
Neural degeneration in the retina of the streptozotocin-induced type 1 diabetes model. Exp Diabetes Res (2011) 0.94
ACE inhibition salvages the visual loss caused by diabetes. Diabetologia (2003) 0.93
Early nephropathy predicts vision-threatening retinal disease in patients with type I diabetes mellitus. J Am Soc Nephrol (1998) 0.92
Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture. J Ophthalmol (2011) 0.92
Intravitreal ranibizumab (lucentis) for the treatment of diabetic macular edema: a systematic review and meta-analysis of randomized clinical control trials. Curr Eye Res (2012) 0.91
Turning a blind eye to anti-VEGF toxicities. J Clin Invest (2012) 0.91
Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications. Ther Apher Dial (2009) 0.91
Visual and anatomical outcomes following vitrectomy for complications of diabetic retinopathy: the DRIVE UK study. Eye (Lond) (2012) 0.91
Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy. Acta Ophthalmol (2011) 0.90
Diabetic macular edema. Dev Ophthalmol (2010) 0.90
Low-dose erythropoietin inhibits oxidative stress and early vascular changes in the experimental diabetic retina. Diabetologia (2010) 0.90
The role of Humphrey Matrix testing in the early diagnosis of retinopathy in type 1 diabetes. Br J Ophthalmol (2008) 0.89
Diabetes impairs the neuroprotective properties of retinal alpha-crystallins. Invest Ophthalmol Vis Sci (2011) 0.89
Intravitreal injection of erythropoietin protects against retinal vascular regression at the early stage of diabetic retinopathy in streptozotocin-induced diabetic rats. Exp Eye Res (2012) 0.89
Visual fields correlate better than visual acuity to severity of diabetic retinopathy. Diabetologia (2005) 0.89
Renin-Angiotensin system hyperactivation can induce inflammation and retinal neural dysfunction. Int J Inflam (2012) 0.89
Global flash multifocal electroretinogram: early detection of local functional changes and its correlations with optical coherence tomography and visual field tests in diabetic eyes. Doc Ophthalmol (2012) 0.89
The effect of the oral PKC β inhibitor ruboxistaurin on vision loss in two phase 3 studies. Invest Ophthalmol Vis Sci (2013) 0.88
Effect of pigment epithelium derived factor on the expression of glutamine synthetase in early phase of experimental diabetic retinopathy. Ocul Immunol Inflamm (2011) 0.88
Erythropoietin produced by the retina: its role in physiology and diabetic retinopathy. Endocrine (2011) 0.88
A prospective, randomized comparison of intravitreal triamcinolone acetonide versus intravitreal bevacizumab (avastin) in diffuse diabetic macular edema. Middle East Afr J Ophthalmol (2010) 0.87
Advanced glycation end products and diabetic retinopathy. Amino Acids (2011) 0.87
Management of diabetic retinopathy: could lipid-lowering be a worthwhile treatment modality? Eye (Lond) (2009) 0.86
Complications of intravitreal triamcinolone acetonide for macular edema and predictive factors for intraocular pressure elevation. Int J Ophthalmol (2012) 0.86
Increased expression of αA-crystallin in human diabetic eye. Int J Mol Med (2011) 0.85
Retinal function in relation to improved glycaemic control in type 1 diabetes. Diabetologia (2011) 0.84
Impact of diabetes on alpha-crystallins and other heat shock proteins in the eye. J Ocul Biol Dis Infor (2011) 0.82
Potential therapeutic effects of pigment epithelium-derived factor for treatment of diabetic retinopathy. Int J Ophthalmol (2013) 0.82